Integra LifeSciences Introduces Next-Generation Licox(R) Brain Tissue Oxygen Monitoring System
PLAINSBORO, N.J., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the introduction of the next-generation Licox® Brain Tissue Oxygen Monitoring System. The Licox system continually monitors brain oxygen partial pressure (PtO2) in patients who have sustained a traumatic brain injury or cerebral vascular event. The Licox system provides clinicians with early warning of hypoxic events, allowing more timely intervention to restore oxygen delivery to the vital tissues of the brain. It is the most widely studied and documented direct cerebral tissue oxygen monitoring device available to the clinician, and has been widely used in neurocritical care since it was launched in the United States in 2001. The new Licox system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), and will be featured at the Congress of Neurological Surgeons (CNS) annual meeting, October 19 - 23, 2013, in San Francisco, California.
Integra's next-generation Licox system incorporates many new features that make it easier to monitor the neuro-compromised patient. The new features include parallel five-day data storage and trending, with a large, touch-screen interface for immediate access to current and historical critical patient data; a compact, lightweight ergonomic design that speeds bedside setup; a 1.5 hour battery life enabling continuous patient monitoring during transport; and a direct plug-and-play interface with Integra's Camino® ICP Monitor, to provide for multi-parameter monitoring.
"Clinical practice and research demonstrate that advanced multi-parameter monitoring plays a critical role in the management of neurotrauma patients and in preventing or reducing secondary injuries caused by hypoxic events," said Simon Archibald, Integra's Chief Scientific Officer. "The redesigned Licox system is a robust, practical and easy-to-use clinical tool for recording cerebral tissue oxygenation. Paired with the new Camino monitor, the Licox system creates our next-generation neuromonitoring platform designed to provide clinicians with critical insight into the cerebral oxygenation, ICP and brain temperature status of their patients."
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com